Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Insulet Corporation (NASDAQ:PODD – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 173,480 shares of the medical instruments supplier’s stock, valued at approximately $26,412,000. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.25% of Insulet at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the company. Glenmede Investment Management LP grew its position in shares of Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC lifted its holdings in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares during the last quarter. Great Lakes Advisors LLC lifted its holdings in Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after acquiring an additional 40 shares during the last quarter. Camarda Financial Advisors LLC lifted its holdings in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after acquiring an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period.
Analysts Set New Price Targets
PODD has been the topic of a number of research reports. Wells Fargo & Company cut Insulet from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. Citigroup boosted their price objective on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. restated a “neutral” rating and set a $152.00 price objective (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Bank of America lowered their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, Sanford C. Bernstein dropped their target price on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Insulet currently has an average rating of “Hold” and a consensus target price of $195.40.
Insulet News Summary
Here are the key news stories impacting Insulet this week:
- Negative Sentiment: Multiple law firms announced or promoted a securities class action against Insulet and certain executives. The complaints allege that the company made materially false or misleading statements about manufacturing controls, product quality, and the safety and reliability of Omnipod devices. The allegations have not been proven in court. Pomerantz class action announcement
- Negative Sentiment: The investor notices link the case to two Omnipod medical-device corrections and claim that related disclosures contributed to a substantial decline in Insulet’s stock. One notice cited a move from $236.07 to $146.01 across the alleged corrective disclosures, or losses exceeding $90 per share for some investors. SueWallSt investor notice
- Negative Sentiment: The legal overhang intensified as several firms—including Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Glancy Prongay, Robbins LLP, Levi & Korsinsky, and Portnoy—urged affected shareholders to seek lead-plaintiff status or evaluate potential recovery. The deadline to move for lead-plaintiff appointment is August 31, 2026. Robbins Geller deadline announcement
Insiders Place Their Bets
In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.
Insulet Trading Down 3.1%
Shares of Insulet stock opened at $146.87 on Friday. The business has a fifty day simple moving average of $154.70 and a 200-day simple moving average of $185.07. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The firm has a market cap of $10.19 billion, a price-to-earnings ratio of 27.45, a price-to-earnings-growth ratio of 1.19 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.
Insulet (NASDAQ:PODD – Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.Insulet’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.
About Insulet
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Stories
- Five stocks we like better than Insulet
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
